Heart failure is a common manifestation of Chagas’ disease and results in significant morbidity and mortality in affected patients. In light of limited data on therapeutic options for heart failure due to Chagas’ disease, the PARACHUTE-HF trial aimed to compare the effects of sacubitril/valsartan versus enalapril on clinical endpoints and changes in natriuretic peptides in this population. This mini-review contextualizes the results of the trial, which demonstrated that sacubitril/valsartan led to significant improvements in outcomes driven primarily by a reduction in natriuretic peptides.
BT - Heart failure reviews C1 - https://www.ncbi.nlm.nih.gov/pubmed/41910669 DA - 03/2026 DO - 10.1007/s10741-026-10617-3 IS - 1 J2 - Heart Fail Rev LA - ENG M3 - Article N2 -Heart failure is a common manifestation of Chagas’ disease and results in significant morbidity and mortality in affected patients. In light of limited data on therapeutic options for heart failure due to Chagas’ disease, the PARACHUTE-HF trial aimed to compare the effects of sacubitril/valsartan versus enalapril on clinical endpoints and changes in natriuretic peptides in this population. This mini-review contextualizes the results of the trial, which demonstrated that sacubitril/valsartan led to significant improvements in outcomes driven primarily by a reduction in natriuretic peptides.
PY - 2026 SP - 1 EP - 4 T2 - Heart failure reviews TI - Evaluation of the PARACHUTE-HF trial: role of sacubitril/valsartan compared to enalapril on outcomes in patients with heart failure from Chagas' disease UR - https://pmc.ncbi.nlm.nih.gov/articles/PMC13035569/pdf/10741_2026_Article_10617.pdf VL - 31 SN - 1573-7322 ER -